Search

Your search keyword '"Mori, Nami"' showing total 236 results
Start Over Author "Mori, Nami"
236 results on '"Mori, Nami"'

1. Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma

Author

Mori, Nami, Tamaki, Nobuharu, Takaki, Shintaro, Tsuji, Keiji, Tada, Toshifumi, Nakamura, Shinichiro, Ochi, Hironori, Mashiba, Toshie, Doisaki, Masao, Marusawa, Hiroyuki, Kobashi, Haruhiko, Fujii, Hideki, Ogawa, Chikara, Nonogi, Michiko, Arai, Hirotaka, Uchida, Yasushi, Urawa, Naohito, Narita, Ryoichi, Akahane, Takehiro, Kondo, Masahiko, Yasui, Yutaka, Tsuchiya, Kaoru, Izumi, Namiki, and Kurosaki, Masayuki

Published
2024
Full Text
View/download PDF

2. Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus

Author

Tamaki, Nobuharu, Kurosaki, Masayuki, Yasui, Yutaka, Mori, Nami, Tsuji, Keiji, Hasebe, Chitomi, Joko, Kouji, Akahane, Takehiro, Furuta, Koichiro, Kobashi, Haruhiko, Kimura, Hiroyuki, Yagisawa, Hitoshi, Marusawa, Hiroyuki, Kondo, Masahiko, Kojima, Yuji, Yoshida, Hideo, Uchida, Yasushi, Tada, Toshifumi, Nakamura, Shinichiro, Yasuda, Satoshi, Toyoda, Hidenori, Loomba, Rohit, and Izumi, Namiki

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Liver Cancer, Chronic Liver Disease and Cirrhosis, Rare Diseases, Clinical Research, Prevention, Liver Disease, Infectious Diseases, Emerging Infectious Diseases, Hepatitis, Cancer, Digestive Diseases, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, 4.1 Discovery and preclinical testing of markers and technologies, Good Health and Well Being, Antiviral Agents, Carcinoma, Hepatocellular, Hepacivirus, Hepatitis C, Hepatitis C, Chronic, Humans, Liver Cirrhosis, Liver Neoplasms, Risk Assessment, Risk Factors, Clinical sciences
Abstract

The identification of patients with advanced fibrosis who do not need any further hepatocellular carcinoma (HCC) surveillance after the eradication of hepatitis C is pivotal. In this study, we developed a simple serum-based risk model that could identify patients with low-risk HCC. This was a nationwide multicenter study involving 16 Hospitals in Japan. Patients with advanced fibrosis (1,325 in a derivation cohort and 508 in a validation cohort) who achieved sustained virological responses at 24 weeks after treatment (SVR24) were enrolled. The HCC risk model at any point after SVR24 and its change were evaluated, and subsequent HCC development was analyzed. Based on the multivariable analysis, patients fulfilling all of the factors (GAF4 criteria: gamma-glutamyl transferase

Published
2022

3. Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus

Author

Tamaki, Nobuharu, Kurosaki, Masayuki, Yasui, Yutaka, Mori, Nami, Tsuji, Keiji, Hasebe, Chitomi, Joko, Koji, Akahane, Takehiro, Furuta, Koichiro, Kobashi, Haruhiko, Kimura, Hiroyuki, Yagisawa, Hitoshi, Marusawa, Hiroyuki, Kondo, Masahiko, Kojima, Yuji, Yoshida, Hideo, Uchida, Yasushi, Loomba, Rohit, and Izumi, Namiki

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Digestive Diseases, Hepatitis, Cancer, Clinical Research, Liver Disease, Rare Diseases, Chronic Liver Disease and Cirrhosis, Liver Cancer, Good Health and Well Being, Antiviral Agents, Carcinoma, Hepatocellular, Hepacivirus, Hepatitis C, Chronic, Humans, Liver Cirrhosis, Liver Neoplasms, Risk Factors, Sustained Virologic Response, FIB-4, hepatocellular carcinoma, SVR, DAA, Biological Sciences, Medical and Health Sciences, Microbiology, Clinical sciences
Abstract

BackgroundIt is unclear whether the fibrosis 4 index (FIB-4), a marker of liver fibrosis, at baseline and change in FIB-4 after sustained virological response (SVR) is associated with incident hepatocellular carcinoma (HCC) risk. In this study, we examined the association of incident HCC risk with baseline FIB-4 and sustained high FIB-4 (>3.25) at any time point after SVR.MethodsA total of 3823 patients who received direct-acting antiviral treatment and achieved SVR were enrolled. The FIB-4 was measured 24 weeks after the end of direct-acting antiviral treatment and achievement of SVR (SVR24), and 1, 2, and 3 years after SVR24, after which subsequent HCC development was investigated.ResultsIn patients with an FIB-4 >3.25 at SVR24 and 1, 2, and 3 years after SVR24, subsequent HCC development was significantly higher than in those with an FIB-4 ≤3.25 at each point. The rates of HCC development 1, 2, 3, and 4 years after SVR24 were significantly higher in patients with sustained FIB-4 >3.25 than in those whose FIB-4 decreased to ≤3.25 (5.4%, 9.2%, 11.7%, and 16.0%, respectively, vs 2.2%, 3.1%, 3.7%, and 4.4%; P 3.25 at SVR24 and 1, 2, and 3 years later were 3.38 (2.4-4.8), 2.95 (1.9-4.7), 2.62 (1.3-5.1), and 3.37 (1.4-9.8), respectively.ConclusionsThe FIB-4 could be used to assess HCC development risk at any time after SVR, and changes in FIB-4 were associated with changes in the HCC development risk. Repeated assessments of FIB-4 could serve as a prognostic indicator of a high-risk HCC cohort that may require more intensive HCC surveillance strategy.

Published
2021

4. Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group

Author

Takaki, Shintaro, Kurosaki, Masayuki, Mori, Nami, Tsuji, Keiji, Ochi, Hironori, Marusawa, Hiroyuki, Nakamura, Shinichiro, Tada, Toshifumi, Narita, Ryoichi, Uchida, Yasushi, Akahane, Takehiro, Kondo, Masahiko, Kusakabe, Atsunori, Furuta, Koichiro, Kobashi, Haruhiko, Arai, Hirotaka, Nonogi, Michiko, Tamada, Takashi, Hasebe, Chitomi, Ogawa, Chikara, Sato, Takashi, Tamaki, Nobuharu, Yasui, Yutaka, Tsuchiya, Kaoru, and Izumi, Namiki

Published
2023
Full Text
View/download PDF

5. Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab

Author

Tamaki, Nobuharu, Tada, Toshifumi, Kurosaki, Masayuki, Yasui, Yutaka, Ochi, Hironori, Mashiba, Toshie, Sakamoto, Azusa, Marusawa, Hiroyuki, Narita, Ryoichi, Uchida, Yasushi, Akahane, Takehiro, Kondo, Masahiko, Mori, Nami, Takaki, Shintaro, Tsuji, Keiji, Kobashi, Haruhiko, Kusakabe, Atsunori, Furuta, Koichiro, Arai, Hirotaka, Nonogi, Michiko, Ogawa, Chikara, Sato, Takashi, Tamada, Takashi, Nakamura, Shinichiro, Hasebe, Chitomi, Tsuchiya, Kaoru, and Izumi, Namiki

Published
2022
Full Text
View/download PDF

6. Viral eradication reduces all‐cause mortality in patients with chronic hepatitis C virus infection who had received direct‐acting antiviral therapy.

Author

Tada, Toshifumi, Kurosaki, Masayuki, Toyoda, Hidenori, Tamaki, Nobuharu, Yasui, Yutaka, Nakamura, Shinichiro, Mori, Nami, Tsuji, Keiji, Ochi, Hironori, Akahane, Takehiro, Kobashi, Haruhiko, Fujii, Hideki, Marusawa, Hiroyuki, Kondo, Masahiko, Urawa, Naohito, Yoshida, Hideo, Uchida, Yasushi, Morita, Atsuhiro, Hasebe, Chitomi, and Mitsuda, Akeri

Subjects
HEPATITIS C, CHRONIC hepatitis C, HEPATITIS C virus, PROPENSITY score matching, DEATH rate
Abstract

Background and Aims: The impact of hepatitis C virus (HCV) eradication via direct‐acting antiviral (DAA) therapy on overall mortality, particularly non‐liver‐related mortality, is understudied. Methods: We recruited 4180 patients with chronic HCV infection who achieved sustained virological response (SVR) (HCV eradication) through DAA therapy (n = 2501, SVR group) or who did not receive antiviral therapy (n = 1679, non‐SVR group); 1236 from each group were chosen using propensity score matching. Causes of death and all‐cause mortality, including non‐liver‐related diseases, were investigated. Results: Of the 4180 patients, 592 died during the follow‐up period. In the SVR group, the mortality rates from liver‐related and non‐liver‐related diseases were 16.5% and 83.5%, respectively. Compared to the non‐SVR group, mortality rates from liver‐related and non‐liver‐related diseases were 50.1% and 49.9%, respectively (p <.001). In non‐cirrhotic patients, multivariable analysis revealed that SVR was an independent factor associated with both liver‐related (hazard ratio [HR],.251; 95% confidence interval [CI],.092–.686) and non‐liver‐related (HR,.641; 95% CI,.415–.990) mortalities. In cirrhotic patients, multivariable analysis revealed that SVR remained an independent factor significantly associated with liver‐related mortality (HR,.151; 95% CI,.081–.279). In propensity score‐matched patients, the eradication of HCV (SVR group) decreased both liver‐related (p <.001) and non‐liver‐related mortality (p =.008) rates compared to persistent HCV infection (non‐SVR group). Conclusions: The elimination of HCV via DAA therapy reduced not only liver‐related mortality but also non‐liver‐related mortality in patients with chronic HCV. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Effect of treatment periods on efficacy of glecaprevir and pibrentasvir in chronic hepatitis C: A nationwide, prospective, multicenter study

Author

Morita, Atsuhiro, primary, Tamaki, Nobuharu, additional, Kobashi, Haruhiko, additional, Mori, Nami, additional, Tsuji, Keiji, additional, Takaki, Shintaro, additional, Hasebe, Chitomi, additional, Akahane, Takehiro, additional, Ochi, Hironori, additional, Mashiba, Toshie, additional, Urawa, Naohito, additional, Fujii, Hideki, additional, Mitsuda, Akeri, additional, Kondo, Masahiko, additional, Ogawa, Chikara, additional, Uchida, Yasushi, additional, Narita, Ryoichi, additional, Marusawa, Hiroyuki, additional, Kubotsu, Yoshihito, additional, Matsushita, Tomomichi, additional, Shigeno, Masaya, additional, Yoshida, Hideo, additional, Tanaka, Katsuaki, additional, Okamoto, Eisuke, additional, Kasai, Toyotaka, additional, Ishii, Toru, additional, Okada, Kazuhiko, additional, Kurosaki, Masayuki, additional, and Izumi, Namiki, additional

Published
2024
Full Text
View/download PDF

10. Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection

Author

Cheng, Xiaoming, Uchida, Takuro, Xia, Yuchen, Umarova, Regina, Liu, Chun-Jen, Chen, Pei-Jer, Gaggar, Anuj, Suri, Vithika, Mucke, Marcus M., Vermehren, Johannes, Zeuzem, Stefan, Teraoka, Yuji, Osawa, Mitsutaka, Aikata, Hiroshi, Tsuji, Keiji, Mori, Nami, Hige, Shuhei, Karino, Yoshiyasu, Imamura, Michio, Chayama, Kazuaki, and Liang, T. Jake

Subjects
United States. Food and Drug Administration, Sofosbuvir -- Health aspects, Backup software -- Health aspects, Biological response modifiers -- Health aspects, Medical research -- Health aspects, Infection -- Health aspects, Hepatitis C virus -- Health aspects, Interferon -- Health aspects, Comorbidity -- Health aspects, Hepatitis B -- Health aspects, Backup software, Health care industry
Abstract

In patients with HBV and HCV coinfection, HBV reactivation leading to severe hepatitis has been reported with the use of direct-acting antivirals (DAAs) to treat HCV infection. Here we studied the molecular mechanisms behind this viral interaction. In coinfected cell culture and humanized mice, HBV replication was suppressed by HCV coinfection. In vitro, HBV suppression was attenuated when interferon (IFN) signaling was blocked. In vivo, HBV viremia, after initial suppression by HCV superinfection, rebounded following HCV clearance by DAA treatment that was accompanied by a reduced hepatic IFN response. Using blood samples of coinfected patients, IFN-stimulated gene products including C-X-C motif chemokine 10 (CXCL10), C-C motif chemokine ligand 5 (CCL5), and alanine aminotransferase (ALT) were identified to have predictive value for HBV reactivation after HCV clearance. Taken together, our data suggest that HBV reactivation is a result of diminished hepatic IFN response following HCV clearance and identify serologic markers that can predict HBV reactivation in DAA-treated HBV-HCV-coinfected persons., Introduction Hepatitis B virus (HBV) and hepatitis C virus (HCV) together infect more than 300 million people worldwide. Due to the shared modes of transmission and epidemiological features, they frequently [...]

Published
2020
Full Text
View/download PDF

11. Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab.

Author

Kikugawa, Chihiro, Uchikawa, Shinsuke, Kawaoka, Tomokazu, Kinami, Takahiro, Yano, Shigeki, Amioka, Kei, Naruto, Kensuke, Ando, Yuwa, Yamaoka, Kenji, Tsuge, Masataka, Kosaka, Yumi, Ohya, Kazuki, Mori, Nami, Takaki, Shintaro, Tsuji, Keiji, Kouno, Hirotaka, Kohno, Hiroshi, Morio, Kei, Moriya, Takashi, and Nonaka, Michihiro

Subjects
LIVER physiology, THERAPEUTIC use of antineoplastic agents, COMBINATION drug therapy, PEARSON correlation (Statistics), STATISTICAL significance, BEVACIZUMAB, FISHER exact test, LOGISTIC regression analysis, SORAFENIB, TREATMENT effectiveness, RETROSPECTIVE studies, MANN Whitney U Test, CHI-squared test, MULTIVARIATE analysis, DESCRIPTIVE statistics, IMMUNE checkpoint inhibitors, LONGITUDINAL method, KAPLAN-Meier estimator, LOG-rank test, LUNG tumors, STATISTICS, CANCER patient psychology, PROGRESSION-free survival, DATA analysis software, HEPATOCELLULAR carcinoma, LIVER function tests, OVERALL survival, PROPORTIONAL hazards models
Abstract

Introduction: Systemic therapy is recommended for patients with Child-Pugh A in hepatocellular carcinoma (HCC). We analyzed the outcomes of a cohort of patients with HCC who received either sorafenib (Sor), lenvatinib (Len) or atezolizumab plus bevacizumab (Atezo + Bev) as first-line systemic therapy for HCC, with the aim of identifying prognostic factors for survival. Methods: A total of 825 patients with advanced HCC and Child-Pugh A or B received either Sor, Len or Atezo + Bev as first-line systemic therapy. Liver function was assessed according to the Child-Pugh score and the modified albumin-bilirubin (mALBI) grade. Results: Prognosis was analyzed according to liver function such as Child-Pugh classifications, scores, and mALBI grades that worsened with a decline in liver function (p <0.001 for all). A Child-Pugh score of 7 was a factor significantly associated with OS. In patients with a Child-Pugh score of 7, an mALBI grade of 3 was an independent predictor of OS. In Child-Pugh B patients with HCC, receiving Atezo + Bev was identified as a factor associated with PFS. Conclusion: Determining the hepatic reserve of patients with unresectable HCC might be useful for identifying patents suitable for systemic treatment for HCC. Atezo + Bev might prolong the PFS of patients with a Child-Pugh score of 7. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma

Author

Yano, Shigeki, primary, Kawaoka, Tomokazu, additional, Yamasaki, Shintaro, additional, Johira, Yusuke, additional, Kosaka, Masanari, additional, Shirane, Yuki, additional, Miura, Ryoichi, additional, Amioka, Kei, additional, Naruto, Kensuke, additional, Yamaoka, Kenji, additional, Fujii, Yasutoshi, additional, Uchikawa, Shinsuke, additional, Fujino, Hatsue, additional, Ono, Atsushi, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Miki, Daiki, additional, Tsuge, Masataka, additional, Teraoka, Yuji, additional, Kouno, Hirotaka, additional, Takaki, Shintaro, additional, Mori, Nami, additional, Tsuji, Keiji, additional, and Oka, Shiro, additional

Published
2023
Full Text
View/download PDF

13. Outcomes of patients with Child-Pugh B and unresectable hepatocellular carcinoma undergoing first-line systemic treatment with sorafenib, lenvatinib, or atezolizumab plus bevacizumab

Author

Kikugawa, Chihiro, primary, Uchikawa, Shinsuke, additional, Kawaoka, Tomokazu, additional, Kinami, Takahiro, additional, Yano, Shigeki, additional, Amioka, Kei, additional, Naruto, Kensuke, additional, Ando, Yuwa, additional, Yamaoka, Kenji, additional, Tsuge, Masataka, additional, Kosaka, Yumi, additional, Ohya, Kazuki, additional, Mori, Nami, additional, Takaki, Shintaro, additional, Tsuji, Keiji, additional, Kouno, Hirotaka, additional, Kohno, Hiroshi, additional, Morio, Kei, additional, Moriya, Takashi, additional, Nonaka, Michihiro, additional, Aisaka, Yasuyuki, additional, Masaki, Keiichi, additional, Honda, Yohji, additional, Naeshiro, Noriaki, additional, Hiramatsu, Akira, additional, Aikata, Hiroshi, additional, and Oka, Shiro, additional

Published
2023
Full Text
View/download PDF

14. Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group

Author

Tsuji, Keiji, Kurosaki, Masayuki, Itakura, Jun, Mori, Nami, Takaki, Shintaro, Hasebe, Chitomi, Akahane, Takehiro, Joko, Kouji, Yagisawa, Hitoshi, Takezawa, Jirou, Nakata, Ryou, Kusakabe, Atsunori, Kojima, Yuji, Kimura, Hiroyuki, Tamada, Takashi, Kobashi, Haruhiko, Mitsuda, Akeri, Kondou, Masahiko, Ogawa, Chikara, Uchida, Yasushi, Sohda, Tetsuro, Narita, Ryouichi, and Izumi, Namiki

Published
2018
Full Text
View/download PDF

15. Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study

Author

Kawakami, Yoshiiku, Ochi, Hidenori, Hayes, Clair Nelson, Imamura, Michio, Tsuge, Masataka, Nakahara, Takashi, Katamura, Yoshio, Kohno, Hiroshi, Kohno, Hirotaka, Tsuji, Keiji, Takaki, Shintaro, Mori, Nami, Honda, Yohji, Arataki, Keiko, Takahashi, Shoichi, Kira, Shinsuke, Tamura, Toru, Masuda, Kazunari, Nakamura, Toshio, Kikkawa, Masaya, and Chayama, Kazuaki

Published
2018
Full Text
View/download PDF

16. Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan

Author

Suda, Goki, Furusyo, Norihiro, Toyoda, Hidenori, Kawakami, Yoshiiku, Ikeda, Hiroki, Suzuki, Michihiro, Arataki, Keiko, Mori, Nami, Tsuji, Keiji, Katamura, Yoshio, Takaguchi, Koichi, Ishikawa, Toru, Tsuji, Kunihiko, Shimada, Noritomo, Hiraoka, Atsushi, Yamsaki, Sho, Nakai, Masato, Sho, Takuya, Morikawa, Kenichi, Ogawa, Koji, Kudo, Mineo, Nagasaka, Atsushi, Furuya, Ken, Yamamoto, Yoshiya, Kato, Kanji, Ueno, Yoshiyuki, Iio, Etsuko, Tanaka, Yasuhito, Kurosaki, Masayuki, Kumada, Takashi, Chayama, Kazuaki, and Sakamoto, Naoya

Published
2018
Full Text
View/download PDF

17. Necessity for surveillance for hepatocellualr carcinoma in older patients with chronic hepatitis C who achieved sustained virological response

Author

Ishido, Shun, primary, Tamaki, Nobuharu, additional, Kurosaki, Masayuki, additional, Mori, Nami, additional, Tsuji, Keiji, additional, Hasebe, Chitomi, additional, Mashiba, Toshie, additional, Ochi, Hironori, additional, Yasui, Yutaka, additional, Akahane, Takehiro, additional, Furuta, Koichiro, additional, Kobashi, Haruhiko, additional, Fujii, Hideki, additional, Ishii, Toru, additional, Marusawa, Hiroyuki, additional, Kondo, Masahiko, additional, Kusakabe, Atsunori, additional, Yoshida, Hideo, additional, Uchida, Yasushi, additional, Tada, Toshifumi, additional, Nakamura, Shinichiro, additional, Mitsuda, Akari, additional, Ogawa, Chikara, additional, Arai, Hirotaka, additional, Murohisa, Toshimitsu, additional, Uebayashi, Minoru, additional, and Izumi, Namiki, additional

Published
2023
Full Text
View/download PDF

19. Analysis of Lenvatinib’s Efficacy against Intermediate-Stage Unresectable Hepatocellular Carcinoma

Author

Amioka, Kei, primary, Kawaoka, Tomokazu, additional, Kinami, Takahiro, additional, Yamasaki, Shintaro, additional, Kosaka, Masanari, additional, Johira, Yusuke, additional, Yano, Shigeki, additional, Naruto, Kensuke, additional, Ando, Yuwa, additional, Fujii, Yasutoshi, additional, Uchikawa, Shinsuke, additional, Ono, Atsushi, additional, Yamauchi, Masami, additional, Imamura, Michio, additional, Kosaka, Yumi, additional, Ohya, Kazuki, additional, Mori, Nami, additional, Takaki, Shintaro, additional, Tsuji, Keiji, additional, Masaki, Keiichi, additional, Honda, Yoji, additional, Kouno, Hirotaka, additional, Kohno, Hioshi, additional, Morio, Kei, additional, Moriya, Takashi, additional, Naeshiro, Noriaki, additional, Nonaka, Michihiro, additional, Aisaka, Yasuyuki, additional, Azakami, Takahiro, additional, Hiramatsu, Akira, additional, Aikata, Hiroshi, additional, and Oka, Shiro, additional

Published
2022
Full Text
View/download PDF

20. Usefulness of neutrophil‐to‐lymphocyte ratio in predicting progression and survival outcomes after atezolizumab–bevacizumab treatment for hepatocellular carcinoma

Author

Ochi, Hironori, primary, Kurosaki, Masayuki, additional, Joko, Kouji, additional, Mashiba, Toshie, additional, Tamaki, Nobuharu, additional, Tsuchiya, Kaoru, additional, Marusawa, Hiroyuki, additional, Tada, Toshifumi, additional, Nakamura, Shinichiro, additional, Narita, Ryoichi, additional, Uchida, Yasushi, additional, Akahane, Takehiro, additional, Kondo, Masahiko, additional, Mori, Nami, additional, Takaki, Shintaro, additional, Tsuji, Keiji, additional, Kusakabe, Atsunori, additional, Furuta, Koichiro, additional, Kobashi, Haruhiko, additional, Arai, Hirotaka, additional, Nonogi, Michiko, additional, Tamada, Takashi, additional, Hasebe, Chitomi, additional, and Izumi, Namiki, additional

Published
2022
Full Text
View/download PDF

21. General evaluation score for predicting the development of hepatocellular carcinoma in patients with advanced liver fibrosis associated with hepatitis C virus genotype 1 or 2 after direct‐acting antiviral therapy

Author

Tada, Toshifumi, primary, Kurosaki, Masayuki, additional, Tamaki, Nobuharu, additional, Yasui, Yutaka, additional, Mori, Nami, additional, Tsuji, Keiji, additional, Hasebe, Chitomi, additional, Joko, Koji, additional, Akahane, Takehiro, additional, Furuta, Koichiro, additional, Kobashi, Haruhiko, additional, Fujii, Hideki, additional, Ishii, Toru, additional, Marusawa, Hiroyuki, additional, Kondo, Masahiko, additional, Kojima, Yuji, additional, Yoshida, Hideo, additional, Uchida, Yasushi, additional, Nakamura, Shinichiro, additional, and Izumi, Namiki, additional

Published
2022
Full Text
View/download PDF

22. Emergence of drug resistance‐associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir‐treated chronic hepatitis C patients

Author

Kan, Hiromi, Imamura, Michio, Kawakami, Yoshiiku, Daijo, Kana, Teraoka, Yuji, Honda, Fumi, Nakamura, Yuki, Morio, Kei, Kobayashi, Tomoki, Nakahara, Takashi, Nagaoki, Yuko, Kawaoka, Tomokazu, Tsuge, Masataka, Aikata, Hiroshi, Hayes, Clair Nelson, Miki, Daiki, Ochi, Hidenori, Honda, Yoji, Mori, Nami, Takaki, Shintaro, Tsuji, Keiji, and Chayama, Kazuaki

Published
2017
Full Text
View/download PDF

23. Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients

Author

Morio, Kei, Imamura, Michio, Kawakami, Yoshiiku, Morio, Reona, Kobayashi, Tomoki, Yokoyama, Satoe, Nagaoki, Yuko, Kawaoka, Tomokazu, Tsuge, Masataka, Hiramatsu, Akira, Makokha, Grace Naswa, Hayes, Nelson C, Aikata, Hiroshi, Miki, Daiki, Ochi, Hidenori, Honda, Yoji, Mori, Nami, Takaki, Shintaro, Tsuji, Keiji, and Chayama, Kazuaki

Published
2017
Full Text
View/download PDF

26. Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma

Author

Amioka, Kei, primary, Kawaoka, Tomokazu, additional, Kosaka, Masanari, additional, Johira, Yusuke, additional, Shirane, Yuki, additional, Miura, Ryoichi, additional, Murakami, Serami, additional, Yano, Shigeki, additional, Naruto, Kensuke, additional, Ando, Yuwa, additional, Kosaka, Yumi, additional, Fujii, Yasutoshi, additional, Kodama, Kenichiro, additional, Uchikawa, Shinsuke, additional, Fujino, Hatsue, additional, Ono, Atsushi, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Okamoto, Wataru, additional, Yamauchi, Masami, additional, Imamura, Michio, additional, Mori, Nami, additional, Takaki, Shintaro, additional, Tsuji, Keiji, additional, Masaki, Keiichi, additional, Honda, Yoji, additional, Kouno, Hirotaka, additional, Kohno, Hiroshi, additional, Moriya, Takashi, additional, Naeshiro, Noriaki, additional, Nonaka, Michihiro, additional, Hyogo, Hideyuki, additional, Aisaka, Yasuyuki, additional, Azakami, Takahiro, additional, Hiramatsu, Akira, additional, and Aikata, Hiroshi, additional

Published
2022
Full Text
View/download PDF

27. A validation study of after direct‐acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct‐acting antiviral therapy and achieved sustained virological response

Author

Tada, Toshifumi, primary, Kurosaki, Masayuki, additional, Tamaki, Nobuharu, additional, Yasui, Yutaka, additional, Mori, Nami, additional, Tsuji, Keiji, additional, Hasebe, Chitomi, additional, Joko, Koji, additional, Akahane, Takehiro, additional, Furuta, Koichiro, additional, Kobashi, Haruhiko, additional, Kimura, Hiroyuki, additional, Yagisawa, Hitoshi, additional, Marusawa, Hiroyuki, additional, Kondo, Masahiko, additional, Kojima, Yuji, additional, Yoshida, Hideo, additional, Uchida, Yasushi, additional, Nakamura, Shinichiro, additional, and Izumi, Namiki, additional

Published
2021
Full Text
View/download PDF

28. Portosystemic encephalopathy with hepatitis C cirrhosis after achieving SVR managed by percutaneous transhepatic shunt obliteration and portal systemic shunt disconnection

Author

Sasaki, Yui, primary, Takaki, Shintaro, additional, Fukuhara, Takayuki, additional, Ohya, Kazuki, additional, Morio, Kei, additional, Miyaki, Eisuke, additional, Mori, Nami, additional, Okanobu, Hideharu, additional, Ochi, Hidenori, additional, Kakizawa, Hideaki, additional, Tsuji, Keiji, additional, and Furukawa, Yoshinari, additional

Published
2021
Full Text
View/download PDF

29. Usefulness of neutrophil‐to‐lymphocyte ratio in predicting progression and survival outcomes after atezolizumab–bevacizumab treatment for hepatocellular carcinoma.

Author

Ochi, Hironori, Kurosaki, Masayuki, Joko, Kouji, Mashiba, Toshie, Tamaki, Nobuharu, Tsuchiya, Kaoru, Marusawa, Hiroyuki, Tada, Toshifumi, Nakamura, Shinichiro, Narita, Ryoichi, Uchida, Yasushi, Akahane, Takehiro, Kondo, Masahiko, Mori, Nami, Takaki, Shintaro, Tsuji, Keiji, Kusakabe, Atsunori, Furuta, Koichiro, Kobashi, Haruhiko, and Arai, Hirotaka

Subjects
NEUTROPHIL lymphocyte ratio, SURVIVAL rate, HEPATOCELLULAR carcinoma, PROPORTIONAL hazards models, VITAMIN K
Abstract

Aim: We investigated pretreatment neutrophil‐to‐lymphocyte ratio (NLR) for predicting survival outcomes of atezolizumab plus bevacizumab therapy for hepatocellular carcinoma (HCC) and determined the predictive ability of combined liver reserve–NLR. Methods: This retrospective, multicenter study enrolled 242 patients receiving atezolizumab plus bevacizumab for unresectable HCC. Pretreatment NLR <2.56 was designated as the "low group" and NLR ≥2.56 as the "high group" (120 and 122 patients, respectively). Propensity score‐matched analysis was undertaken between the low and high groups. Results: In this cohort, the objective response and disease control rates were 20% and 72.5%, respectively, in the low group and 19.6% and 72.9%, respectively, in the high group. After matching, median progression‐free survival (PFS) time was 283 and 167 days in the low and high groups, respectively (p = 0.022). Neutrophil‐to‐lymphocyte ratio ≥2.56 (hazard ratio [HR], 1.54; 95% confidence interval [CI], 1.05–2.28; p = 0.028), modified albumin–bilirubin index (mALBI) grade 2b or 3 (HR 1.55; 95% CI, 1.05–2.29; p = 0.025), and protein induced by vitamin K absence or antagonist‐II ≥ 400 (HR 2.03; 95% CI, 1.36–3.02; p = 0.001) were significantly associated with PFS in univariate analysis using the Cox proportional hazards model. In cases involving mALBI grade 1 or 2a (n = 131), the median PFS time was not reached in the low group, whereas it was 210 days in the high group (p = 0.037). Conclusions: Pretreatment NLR is a simple tool for routine measurement in clinical practice. It can predict PFS in patients with unresectable HCC treated with atezolizumab plus bevacizumab, especially mALBI grade 1 or 2a. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

30. Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus

Author

Tamaki, Nobuharu, primary, Kurosaki, Masayuki, additional, Yasui, Yutaka, additional, Mori, Nami, additional, Tsuji, Keiji, additional, Hasebe, Chitomi, additional, Joko, Kouji, additional, Akahane, Takehiro, additional, Furuta, Koichiro, additional, Kobashi, Haruhiko, additional, Kimura, Hiroyuki, additional, Yagisawa, Hitoshi, additional, Marusawa, Hiroyuki, additional, Kondo, Masahiko, additional, Kojima, Yuji, additional, Yoshida, Hideo, additional, Uchida, Yasushi, additional, Tada, Toshifumi, additional, Nakamura, Shinichiro, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Loomba, Rohit, additional, and Izumi, Namiki, additional

Published
2021
Full Text
View/download PDF

31. Real‐world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1‐ and 2‐infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group

Author

Tada, Toshifumi, primary, Kurosaki, Masayuki, additional, Nakamura, Shinichiro, additional, Hasebe, Chitomi, additional, Kojima, Yuji, additional, Furuta, Koichiro, additional, Kobashi, Haruhiko, additional, Kimura, Hiroyuki, additional, Ogawa, Chikara, additional, Yagisawa, Hitoshi, additional, Uchida, Yasushi, additional, Joko, Kouji, additional, Akahane, Takehiro, additional, Arai, Hirotaka, additional, Marusawa, Hiroyuki, additional, Narita, Ryoichi, additional, Ide, Yasushi, additional, Sato, Takashi, additional, Kusakabe, Atsunori, additional, Tsuji, Keiji, additional, Mori, Nami, additional, Kondo, Masahiko, additional, Mitsuda, Akeri, additional, and Izumi, Namiki, additional

Published
2021
Full Text
View/download PDF

38. A case of jejunal loop varices caused by portal vein occlusion after pancreatoduodenectomy for duodenal cancer successfully treated with interventional radiology via laparotomy

Author

Yamashita, Yumiko, primary, Fukuhara, Takayuki, additional, Takaki, Shintaro, additional, Mori, Nami, additional, Tsuji, Keiji, additional, Kinjou, Nao, additional, Maeda, Takashi, additional, Kakizawa, Hideaki, additional, Masaki, Keiichi, additional, and Furukawa, Yoshinari, additional

Published
2021
Full Text
View/download PDF

39. Clinical Outcomes of 2nd- and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma

Author

Naruto, Kensuke, primary, Kawaoka, Tomokazu, additional, Amioka, Kei, additional, Ogawa, Yutaro, additional, Chihiro, Kikukawa, additional, Yoshikawa, Yuki, additional, Ando, Yuwa, additional, Suehiro, Yosuke, additional, Kosaka, Yumi, additional, Uchikawa, Shinsuke, additional, Kodama, Kenichiro, additional, Morio, Kei, additional, Fujino, Hatsue, additional, Murakami, Eisuke, additional, Nakahara, Takashi, additional, Yamauchi, Masami, additional, Tsuge, Masataka, additional, Hiramatsu, Akira, additional, Fukuhara, Takayuki, additional, Takaki, Shintaro, additional, Mori, Nami, additional, Tsuji, Keiji, additional, Nonaka, Michihiro, additional, Hyogo, Hideyuki, additional, Aisaka, Yasuyuki, additional, Masaki, Keiichi, additional, Honda, Yoji, additional, Kohno, Hirotaka, additional, Kohno, Hiroshi, additional, Moriya, Takashi, additional, Naeshiro, Noriaki, additional, Azakami, Takahiro, additional, Imamura, Michio, additional, Chayama, Kazuaki, additional, and Aikata, Hiroshi, additional

Published
2021
Full Text
View/download PDF

40. Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma

Author

Ando, Yuwa, primary, Kawaoka, Tomokazu, additional, Amioka, Kei, additional, Naruto, Kensuke, additional, Ogawa, Yutaro, additional, Yoshikawa, Yuki, additional, Kikukawa, Chihiro, additional, Kosaka, Yumi, additional, Uchikawa, Shinsuke, additional, Morio, Kei, additional, Fujino, Hatsue, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Yamauchi, Masami, additional, Tsuge, Masataka, additional, Hiramatsu, Akira, additional, Fukuhara, Takayuki, additional, Mori, Nami, additional, Takaki, Shintaro, additional, Tsuji, Keiji, additional, Nonaka, Michihiro, additional, Hyogo, Hideyuki, additional, Aisaka, Yasuyuki, additional, Masaki, Keiichi, additional, Honda, Yoji, additional, Moriya, Takashi, additional, Naeshiro, Noriaki, additional, Takahashi, Shoichi, additional, Imamura, Michio, additional, Chayama, Kazuaki, additional, and Aikata, Hiroshi, additional

Published
2021
Full Text
View/download PDF

41. Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy

Author

Amioka, Kei, primary, Kawaoka, Tomokazu, additional, Ogawa, Yutaro, additional, Kikukawa, Chihiro, additional, Naruto, Kensuke, additional, Yoshikawa, Yuki, additional, Ando, Yuwa, additional, Kosaka, Yumi, additional, Uchikawa, Shinsuke, additional, Morio, Kei, additional, Fujino, Hatsue, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Yamauchi, Masami, additional, Tsuge, Masataka, additional, Hiramatsu, Akira, additional, Imamura, Michio, additional, Fukuhara, Takayuki, additional, Mori, Nami, additional, Takaki, Shintaro, additional, Tsuji, Keiji, additional, Masaki, Keiichi, additional, Honda, Yoji, additional, Kouno, Hirotaka, additional, Kohno, Hiroshi, additional, Chayama, Kazuaki, additional, and Aikata, Hiroshi, additional

Published
2021
Full Text
View/download PDF

43. Efficacy of vonoprazan 10 mg compared with 20 mg for the initial treatment in patients with erosive esophagitis: a randomized pilot study

Author

Okanobu, Hideharu, primary, Kohno, Tomohiko, additional, Mouri, Ritsuo, additional, Hatsushika, Yoshiki, additional, Yamashita, Yumiko, additional, Miyaki, Eisuke, additional, Fukuhara, Takayuki, additional, Okazaki, Akihito, additional, Sakano, Ayaka, additional, Urabe, Ayako, additional, Takaki, Shintaro, additional, Mori, Nami, additional, Tsuji, Keiji, additional, Ochi, Hidenori, additional, and Furukawa, Yoshinari, additional

Published
2020
Full Text
View/download PDF

44. Real‐world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus‐related decompensated cirrhosis

Author

Ohya, Kazuki, primary, Imamura, Michio, additional, Teraoka, Yuji, additional, Morio, Kei, additional, Fujino, Hatsue, additional, Nakahara, Takashi, additional, Ono, Atsushi, additional, Murakami, Eisuke, additional, Kawaoka, Tomokazu, additional, Miki, Daiki, additional, Tsuge, Masataka, additional, Hiramatsu, Akira, additional, Aikata, Hiroshi, additional, Hayes, C. Nelson, additional, Mori, Nami, additional, Takaki, Shintaro, additional, Tsuji, Keiji, additional, Aisaka, Yasuyuki, additional, Ishitobi, Tomokazu, additional, Katamura, Yoshio, additional, Kodama, Hideaki, additional, Nabeshima, Yoshitaka, additional, Masaki, Keiichi, additional, Honda, Yohji, additional, Moriya, Takashi, additional, Kohno, Hirotaka, additional, Kohno, Hiroshi, additional, and Chayama, Kazuaki, additional

Published
2020
Full Text
View/download PDF

45. Plasma Lipid Profiling of Three Types of Drug-Induced Liver Injury in Japanese Patients: A Preliminary Study

Author

Saito, Kosuke, primary, Kagawa, Tatehiro, additional, Tsuji, Keiji, additional, Kumagai, Yuji, additional, Sato, Ken, additional, Sakisaka, Shotaro, additional, Sakamoto, Naoya, additional, Aiso, Mitsuhiko, additional, Hirose, Shunji, additional, Mori, Nami, additional, Tanaka, Rieko, additional, Uraoka, Toshio, additional, Takata, Kazuhide, additional, Ogawa, Koji, additional, Mori, Kazuhiko, additional, Sato, Motonobu, additional, Nishiya, Takayoshi, additional, Takamatsu, Kazuhiko, additional, Arakawa, Noriaki, additional, Izumi, Takashi, additional, Ohno, Yasuo, additional, Saito, Yoshiro, additional, and Takikawa, Hajime, additional

Published
2020
Full Text
View/download PDF

47. Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib

Author

Ando, Yuwa, primary, Kawaoka, Tomokazu, additional, Suehiro, Yosuke, additional, Yamaoka, Kenji, additional, Kosaka, Yumi, additional, Uchikawa, Shinsuke, additional, Kodama, Kenichiro, additional, Morio, Kei, additional, Fujino, Hatsue, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Yamauchi, Masami, additional, Tsuge, Masataka, additional, Hiramatsu, Akira, additional, Fukuhara, Takayuki, additional, Mori, Nami, additional, Takaki, Shintaro, additional, Tsuji, Keiji, additional, Nonaka, Michihiro, additional, Hyogo, Hideyuki, additional, Aisaka, Yasuyuki, additional, Masaki, Keiichi, additional, Honda, Yoji, additional, Moriya, Takashi, additional, Naeshiro, Noriaki, additional, Azakami, Takahiro, additional, Takahashi, Shoichi, additional, Imamura, Michio, additional, Chayama, Kazuaki, additional, and Aikata, Hiroshi, additional

Published
2020
Full Text
View/download PDF

48. Familial Occurrence of a Congenital Portosystemic Shunt of the Portal Vein

Author

Goto, Kumiko, Tsuji, Keiji, Honda, Yohji, Takaki, Shintaro, Mori, Nami, Kakizawa, Hideaki, Kurihara, Sho, Hiyama, Eiso, Furukawa, Yoshinari, and Chayama, Kazuaki

Subjects
Congenital portosystemic shunts of the portal vein, congenital, hereditary, and neonatal diseases and abnormalities, patent ductus venosus, Abernethy malformation, cardiovascular system, cardiovascular diseases
Abstract

A congenital portosystemic shunt of the portal vein is a very rare vascular anomaly associated with the liver. We report the case of a 5-year-old girl with a patent ductus venosus and her 31-year-old mother with a congenital portosystemic shunt. The child presented with a history of an extremely low birth weight in addition to an atrial septal defect and a patent ductus venosus. At the age of 2, she underwent ligation of the ductus venosus. Her mother was also diagnosed with a congenital vascular anomaly at the age of 16. We have followed up and evaluated her asymptomatic mother for 15 years. To our knowledge, this is the first report describing the occurrence of a congenital portosystemic shunt in both a mother and her child.

Published
2017

49. Portosystemic Encephalopathy without Liver Disease Masquerading as Dementia

Author

Honda, Yohji, Kubo, Masami, Takaki, Shintaro, Mori, Nami, Ishikawa, Masaki, Kakizawa, Hideaki, Tsuji, Keiji, and Furukawa, Yoshinari

Subjects
Portosystemic Encephalopathy, Dementia, Portosystemic shunt
Abstract

An 84-year-old woman was hospitalized due to consciousness disorder as hyperammonemia. She had no etiology of liver disease. Twelve months before the current admission, she had been diagnosed with dementia based on her low level of daily perception and physical activity. Abdominal computed tomography revealed a large portosystemic shunt between the medial branch of the portal vein and middle hepatic vein. After the improvement of her consciousness disturbance by medical treatment, percutaneous shunt embolization was electively performed. The patient showed a remarkable clinical improvement. Consciousness disturbance caused by hyper-ammonemia might be underlying in dementia patients. Increase of hepatopetal portal blood flow might have contributed to the improvement of her consciousness disturbance. Embolization of the portosystemic shunt might be more effective for patients without liver disease as in the present case.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results